Skip to main content


We have a robust program of clinical investigation, with specific interests in the following conditions:

  • Pulmonary Hypertension

At the University of Kansas Medical Center, we have a robust clinical and translational science research program with a primary mission of the advancement and treatment of Pulmonary Hypertension. In addition, we are the only designated Pulmonary Hypertension Comprehensive Care Center (PHCCC) in the state of Kansas and the region. We are dedicated to enhancing a better understanding of pulmonary hypertension and finding novel and more efficient ways to treat patients with this life-altering disease.

For additional information about this research, go the pulmonary hypertension research home page.


We are dedicated to advancing treatment and therapies available to individuals with an active COVID-19 infection. We are the only outpatient COVID positive research center in the state of Kansas and in the region. KUMC is also focused on expanding upon research and developing new treatments and testing for individuals that are recovering from COVID-19, are recovered from COVID-19, and have long term post-COVID-19 symptoms ("long haul").

For additional information about this research, go the COVID/Post-COVID research home page.

  • Sepsis

We are highly active in outcomes research and research into the delivery of evidence-based care for sepsis. Specific areas of interest include outcomes of sepsis treatment in rural settings, determinants of outcome in the quaternary medical center, use of electronic early warning systems for sepsis diagnosis, and outcomes in patients with specific conditions, such as hematological malignancies and pulmonary hypertension. We have also worked with members of the School of Engineering at Kansas State University to develop agent-based models of innate immunity in sepsis.

For additional information about this research, visit the sepsis research home page.

  • Airway and Asthma Translational Research Unit (AATRU)

Our research focuses on understanding what causes morbidity from asthma and COPD and how to be prevent or treat these common chronic conditions.

Dr. Mario Castro, MD, MPH, division chief of Pulmonary, Critical Care and Sleep Medicine, Vice Chair for Clinical and Translational Research, director of the Rainbow Clinical and Translational Science Unit (CTSU, Frontiers) leads the AATRU group, which currently has >25 ongoing studies, all of which have opportunities for students, residents, fellows and junior faculty to perform focused research in an area of interest.

For additional information about this research, visit the AATRU home page.

Last modified: Jun 14, 2021